

1 **Disability-adjusted life years (DALYs) due to the direct health impact of COVID-19 in** 2 **India, 2020**

3 Balbir B Singh^{a,b,c}, Brecht Devleesschauwer^{d,e}, Mehar S Khatkar^b, Mark Lowerison^{f,g}, Baljit
4 Singh^{f,h}, Navneet K Dhand^b and Herman W Barkema^{f,g,i}

5 ^aCentre for One Health, Guru Angad Dev Veterinary and Animal Sciences University,
6 Ludhiana, Punjab 141004, India

7 ^bSydney School of Veterinary Science, The University of Sydney, 425 Werombi Road,
8 Camden, 2570 NSW, Australia

9 ^cDept. of Veterinary Microbiology, University of Saskatchewan, Saskatoon, Canada

10 ^dDepartment of Epidemiology and Public Health, Sciensano, Rue Juliette Wytsman 14,
11 BE-1050, Brussels, Belgium

12 ^eDepartment of Veterinary Public Health and Food Safety, Ghent University,
13 Salisburylaan 133, BE-9820, Merelbeke, Belgium

14 ^fDept. of Community Health Sciences, Cumming School of Medicine, University of
15 Calgary, 3330 Hospital Drive NW, Calgary, AB, Canada, T2N 4N1

16 ^gOne Health at UCalgary, University of Calgary, 3330 Hospital Drive NW, Calgary,
17 Canada, T2N 4N1

18 ^hUniversity of Saskatchewan, Saskatoon, SK, Canada

19 ⁱDept. of Production Animal Health, Faculty of Veterinary Medicine, University of
20 Calgary, 3330 Hospital Drive NW, Calgary, Canada, T2N 4N1

21 **Corresponding author:**

22 Balbir B Singh, Professor, Centre for One Health, Guru Angad Dev Veterinary and
23 Animal Sciences University, Ludhiana, Punjab 141004, India

24 Email: bbsdhaliwal@gmail.com; Tel.: +91 161 2414009; Fax: +91 161 2400822

25

26 Abstract

27 COVID-19 has affected all countries. Its containment represents a unique challenge for India
 28 due to a large population (>1.38 billion) across a wide range of population densities.
 29 Assessment of the COVID-19 disease burden is required to put the disease impact into
 30 context and support future pandemic policy development. Here, we present the national-level
 31 burden of COVID-19 in India in 2020 that accounts for differences across urban and rural
 32 regions and across age groups. Disability-adjusted life years (DALY) due to COVID-19 were
 33 estimated in the Indian population in 2020, comprised of years of life lost (YLL) and years
 34 lived with disability (YLD). Scenario analyses were conducted to account for excess deaths
 35 not recorded in the official data and for reported COVID-19 deaths. The direct impact of
 36 COVID-19 in 2020 in India was responsible for 14,106,060 (95% uncertainty interval [UI]
 37 14,030,129–14,213,231) DALYs, consisting of 99.2% (95% UI 98.47–99.64%) YLLs and
 38 0.80% (95% UI 0.36–1.53) YLDs. DALYs were higher in urban (56%; 95% UI 56–57%)
 39 than rural areas (44%; 95% UI 43.4–43.6) and in males (64%) than females (36%). In
 40 absolute terms, the highest DALYs occurred in the 51–60-year-old age group (28%) but the
 41 highest DALYs per 100,000 persons were estimated for the 71–80 year old age group (5,481;
 42 95% UI 5,464–5,500 years). There were 4,823,791 (95% UI 4,760,908–4,924,307) DALYs
 43 after considering reported COVID-19 deaths only. The DALY estimations have direct and
 44 immediate implications not only for public policy in India, but also internationally given that
 45 India represents one sixth of the world's population.

46

47 **Keywords:** COVID-19; Disability-adjusted life years; India; Years lived with disability;
 48 Years of life lost

49 1.0 Introduction

50 The coronavirus disease 2019 (COVID-19) pandemic ¹ originated in Wuhan, China in
 51 December 2019 ² and eventually worldwide. The disease is caused by the severe acute
 52 respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that infects humans ³. As of 30 July
 53 2021, 196,553,009 cumulative cases and 4,200,412 cumulative deaths have been reported
 54 worldwide ⁴. The virus spreads via respiratory droplets, and aerosols shed from infected
 55 individuals ^{5,6} or directly through contaminated hands ⁷. Important symptoms include fever,
 56 respiratory tract symptoms such as cough, pneumonia, shortness of breath and can progress to
 57 serious illness and even death ^{8,9}. In addition, long or post-acute COVID-19 syndrome with
 58 symptoms and abnormalities after 12 weeks following the onset of acute COVID-19
 59 infections has also been recognised ¹⁰.

60 The first case of COVID-19 in India was reported on 30 January 2020. The government of
 61 India implemented staged lockdowns and intense contact mitigation to overcome this
 62 challenge; however, these interventions were only able to slow but did not halt the spread of
 63 COVID-19 in India ¹¹. As of 30 July 2021, 31,572,344 cumulative cases and 423,217
 64 cumulative deaths have been reported in India ⁴. The adjusted case fatality risk (aCFR) due to
 65 COVID-19 in India has been reported to be 1.4 and 3.0% using random- and fixed-effects
 66 models, respectively ¹². At the end of the first wave (15 February 2021), the cumulative aCFR
 67 declined to 1.2% using random and 1.6% using fixed-effects models ¹². The aCFR in India
 68 was associated with co-morbidities such as the incidence of diabetes, cardiovascular diseases,
 69 hypertension, and acute respiratory infections ¹².

70 The health impact of COVID-19 is being investigated across the globe. A recent study
 71 reported 1,279,866 deaths due to COVID-19 in 81 countries with an average of 16 years of
 72 life lost (YLL) per death resulting in 20,507,518 YLL ¹³. In the Kerala state of India, 709.2
 73 DALYs per 100,000 population have been estimated from the inception of the pandemic to

74 20 August 2020¹⁴. However, despite being the second most populous country in the world,
75 no comprehensive assessment of the disease burden of COVID-19 in India has been
76 undertaken. In this study, we estimated DALYs due to the direct health impact of COVID-19
77 in India from 30 January 2020 (the first case reported) to 31 December 2020. Domain,
78 gender, and age-specific DALY estimates are provided to understand health impacts of
79 COVID-19 in India.

80 **2.0 Methods**

81 *2.1 COVID-19 case and death data*

82 The COVID-19 cumulative case and death data till 31 December 2020 were extracted using
83 the Government of India Ministry of Health and Family Welfare (MoHFW) COVID-19
84 tracker on 18 January 2021, 8:00 AM¹⁵. Age-, gender- and domain-specific distributions of
85 COVID-19 cases as provided by the National Centre for Disease Control, Government of
86 India (as of 18 January 2021) were used in the analysis¹⁶. The National Centre for Disease
87 Control data on the proportion of deaths in various age groups as of 2 September 2020 were
88 recorded from the published literature¹⁷. Gender-specific mortality risk (64% in males and
89 36% in females) reported by the MoHFW were also recorded as of 21 May 2020¹⁸. Domain-
90 specific COVID-19 death data (rural vs urban) were obtained from the news item published
91 online (<https://www.downtoearth.org.in/news/health/more-than-half-of-india-s-april-covid-19-deaths-were-in-rural-districts-76782>) indicating 56% deaths in urban and 44% deaths in
92 rural districts during March 2020-April 2021.
93 Several studies indicate 48.5%¹⁹, 52.5%²⁰, and 57.8%²¹ of SARS-CoV-2 infected
94 individuals remained asymptomatic in the country. A systematic review and meta-analysis
95 conducted using the studies conducted worldwide till 10 June 2020 indicated 31% (95% CI
96 26–37%) of infected people to be asymptomatic²². Based on all these studies, we assumed
97 that 31–57.8% of infected people to be asymptomatic in the country.
98

99 As of 17 July 2020, the MoHFW reported that there were 2.8% cases on oxygen beds, 1.9%
 100 cases in intensive care units (ICUs), and 0.35% cases on ventilators²³. As of September 4,
 101 2020, the MoHFW reported updated estimates of 3.5% cases on oxygen beds, 2.0% cases in
 102 ICUs, and 0.50% cases on ventilators²³. Based on both estimates, we assumed 4.8-5.5% of
 103 severe (patients in ICU plus those needing oxygen support), and 0.35-0.5% of critical
 104 (patients on ventilators) cases in the country. The proportion of cases that were not
 105 asymptomatic, severe or critical were assumed to be mild/moderate cases.
 106 No data were available for the proportion of cases having post-acute COVID-19 syndrome
 107 (PCS) from India. A UK COVID symptom study indicates that approximately 10% of
 108 COVID-19 patients suffer from PCS^{24,25}. Other studies report that 51% of the patients in
 109 Spain²⁶ and 32.5% of patients in the United states²⁷ suffer from PCS. Based on the above-
 110 mentioned findings, we assumed that 32.5% of the mild/moderate, severe or critical cases
 111 would suffer from PCS in India. Details of COVID-19 cases and death input data have been
 112 presented in Table S1.

113 2.2 COVID-19 severity data

114 COVID-19 outcomes model and value of health loss as described by Wyper, et al.²⁸ were
 115 used in the current estimations^{29,30}. For COVID-19 infections, disability weight(s) of 0.051
 116 (0.032-0.074) for mild/moderate, 0.133 (0.088-0.190) for severe, 0.655 (0.579-0.727) for
 117 critical, and 0.219 (0.148-0.308) for post-acute consequences cases were used. Per definition,
 118 the disability weight for asymptomatic cases equaled zero.
 119 A mean duration of 7.79 days (6.20 - 9.64 days) has been estimated using meta-analysis for
 120 lower respiratory infections (LRI)³¹. A study from India reported the interval to resolution of
 121 COVID-19 symptoms to be a median of 7.0 days (2.0-9.5 days)³². Similarly, another study
 122 reported a median moderate COVID-19 duration of 6.0 days (3-11 days)³³. Based on all

these estimates, we used a median of 7 days (2-11 days) as the disease duration for mild/moderate COVID-19 in India.

A study from India reported 12 days duration of COVID-19 for hospitalized patients³⁴. Another study from Germany also reported an overall hospitalization of 12 (7–20) days for COVID-19 patients needing oxygen supplementation outside the ICU³⁵. For critical patients, duration in the ICU for 9 (7-11) days has been reported³⁶. A Belgian study reported the time between symptom onset and hospitalization to vary from 3-10.4 days³⁷. Therefore, we used 18 (10-30.4) days as the disease duration for severe and critical COVID-19 (symptom onset to hospitalization duration plus hospitalization duration) in India.

A recent review on PCS indicated the duration of PCS in various countries varied from 1 to 6 months post-symptom onset, with a 2-month duration commonly reported¹⁰. Therefore, we used a median of 60 days (30 – 180 days) as the disease duration for PCS in India. Details of COVID-19 severity-related input data have been presented in Table S1.

2.3 Demographic data

The human population in India for 2020 was projected to be 1,380,004,390³⁸. However, age-, domain- and gender-specific proportions of the population were not available for the year 2020. Therefore, we used the age-, domain- and gender-specific proportion of the population from the 2011 human population census data³⁹ assuming it to be constant for 2011 and 2020 population data. Life expectancy was derived as per the standard life expectancy table of Global Burden of Disease Study 2019⁴⁰. Details of demographic data have been presented in Table S1.

2.4 COVID-19 deaths

Excess deaths due to COVID-19 in India for the year 2020 were estimated (Table S1) using COVID-19 mortality estimates from March 2020 to May 2021 generated by the Institute for Health Metrics and Evaluation, Washington⁴¹. Using the IHME data, the confidence interval

of the proportion of the reported COVID-19 deaths to the excess deaths was estimated⁴². We assumed that there will be a similar proportion of excess deaths during the year 2020 as reported from March 2020 to May 2021. As age, domain, and gender-specific proportion of excess deaths were unavailable, we assumed that the proportion of excess deaths will be similar to those reported for COVID-19 deaths.

2.5 Calculation of disability-adjusted life years

DALYs were estimated as the sum of YLDs and YLLs. YLL was estimated by multiplying the number of deaths due to COVID-19 by the residual standard life expectancy at the age of death due to the disease. YLD was calculated as a product of the number of incident cases of COVID-19, disease duration and disability weight. Domain-, gender- and age-specific DALYs were estimated as per Devleesschauwer et al. 2014a and 2014b^{43,44}. We assumed that cases were sick before dying; therefore, both YLDs and YLLs were estimated for COVID-19 deaths.

Scenario analyses were conducted using a) excess COVID-19 deaths reported by IHME⁴¹, and b) officially reported deaths¹⁵ to estimate DALYs associated with COVID-19 in India. Uncertainty was propagated using 10,000 Monte Carlo simulations. Uniform probability distributions were applied for the proportion of patients having mild/moderate, severe, or critical symptoms. Triangular distribution(s) were applied to disability weights and COVID-19 disease duration associated with various COVID-19 outcomes. A triangular distribution was also applied to excess COVID-19 deaths during the calendar year 2020.

The resulting uncertainty distributions were summarized by their mean and a 95% uncertainty interval (UI) defined as the distribution's 2.5th and 97.5th percentile.

All analyses were conducted using R version 3.6.3 (R Development Core Team, <http://www.r-project.org>).

3.0 Results

3.1 Disability-adjusted life years

The direct impact of COVID-19 was responsible for 14,106,060 DALYs consisting of 13,992,803 (99.2%; 95% UI 98.47–99.64%) YLLs and 113,257 (0.80%; 95% UI 0.36–1.53%) YLDs in 2020 in India (Table 1). There were 7,970,337 DALYs in urban (56%) as compared to 6,135,722 in rural (44%) areas (Table 1). There were 9,028,492 DALYs in males (64.0%) as compared to 5,077,568 DALYs in females (36.0%) (Table 1). The highest DALYs were reported in persons 51-60 years (3,922,508; 28%, Table 2). Mortality contributed towards almost all (99.2%) DALYs due to the direct impact of COVID-19 in India. There were 31.67 YLLs per COVID-19 death in the country. PCS contributed towards 89.61% (95% UI 79.1–95.62%) of the YLDs.

3.2 Disability-adjusted life years per 100,000 people

There were 1,022 DALYs, 1,014 YLLs, and 8 median YLDs per 100,000 persons per year in the country (Table 1). The median DALYs per 100,000 persons per year were higher in urban as compared to rural (1,854 vs 646) and in males as compared to females (1,270 vs 758) in India. The highest DALYs per 100,000 persons per year were at 5,481 (95% UI 5,464–5,500) reported in persons belonging to the age group of 71-80 years in India (Table 2).

3.3 Scenario analyses

The DALYs, YLLs and YLDs were approximately 3 times lower after considering reported COVID-19 deaths only (Table S2). There were 4,823,791 DALYs, 4,710,106 YLLs and 113,685 YLDs due to reported COVID-19 deaths. There were 349 DALYs, 341 YLLs and 8 YLDs per 100,000 persons per year due to reported COVID-19 deaths in the country (Table S2). A proportional decrease in age-wise DALYs and YLLs after excluding excess COVID-19 deaths is also presented in Table S3.

4.0 Discussion

We estimated DALYs due to the direct impact of COVID-19 in 2020 in India. Furthermore, we also accounted for excess COVID-19 deaths (not officially reported) for accurate DALY estimates. As far as we are aware, DALY estimations for COVID-19 for the full 2020 year have not been reported from India. Therefore, the current study will provide valuable insights into health impacts of COVID-19 in 2020 in India.

We believe IHME excess COVID-19 deaths prediction to be accurate, as it was based on models using week-by-week measurements of excess death rate during the ongoing COVID-19 pandemic. Furthermore, 6 drivers of all-cause mortality, including: a) the excess COVID-19 death rate, b) excess mortality due to delayed or deferred health care, c) excess mortality due to mental health disorders, d) reductions in mortality due to decrease in injuries, e) decrease in mortality due to other viruses, and f) and decrease in mortality due to certain chronic conditions, were also taken into account to accurately predict excess COVID-19 deaths nationally and various regions globally⁴¹.

There was a loss of 1,022 healthy years of life per 100,000 person-years and 14 million DALYs due to the direct impact of COVID-19 in 2020 in India. In 2019, there were overall 468 million DALYs in India⁴⁵ indicating that the DALYs due to COVID-19 could account for almost 3% of the total DALYs in India. In 2017, the top 15 causes of DALYs per 1,000 person-years in India ranges from ischaemic heart disease (35.0) to fever of unknown origin (9.0)⁴⁶. Therefore, if excess deaths due to COVID-19 were accounted, the direct impact of COVID-19 would be among the top 15 causes but not among the top 10 of DALYs in 2020 in India. These estimates of direct impact of COVID-19 are lower than ischaemic heart disease, nutritional deficiencies, chronic respiratory diseases, neuropsychiatric conditions, diarrhoea, vision and other sensory loss, respiratory infections, cancers, stroke, road traffic accidents,

tuberculosis, liver and alcohol-related conditions, but higher than musculoskeletal disorders and fever of unknown origin.

There are considerable variations among countries in estimated DALYs. For example, there were 1,767–1,981 DALYs per 100,000 person-years due to COVID-19 during 2020 in Scotland⁴⁷, 4.9 (20 January to 24 April 2020) in Korea⁴⁸, and 368 in Germany in 2020⁴⁹. There were 1200 YLLs per 100,000 capita during the first year of the pandemic in USA⁵⁰. Based on the reported COVID-19 death data, the DALYs per 100,000 person-years were approximately similar to those reported for Germany. However, after accounting for excess COVID-19 deaths, the DALYs per 100,000 person-years were much closer to those reported from the USA.

Median DALYs were higher in urban areas (56%) compared to rural areas. Similarly, urban-rural differences in exposures and outcomes of COVID-19 have been reported in the USA⁵¹. This is because a high number of cases and deaths were reported from urban as compared to rural areas. Perhaps contact patterns are different in urban areas and rural areas. For example, a social contact rate of 17.0 in rural⁵², 28.3 in urban developed centres and 67.4 in urban slum areas⁵³ per person per day was recorded in various domains in India.

Median DALYs were higher in males (64.0%) as compared to females (36.0%). Similar trends have been observed globally. Out of 121,449 DALYs in Italy, 82,020 were in males and 39,429 in females⁵⁴. Higher YLLs have been reported in males in 30 high incidence countries⁵⁵. Gender-specific DALY differences are due to a difference in proportion in cases and deaths among males and females. Furthermore, women have fewer contacts than men outside the home⁵². In addition, being a male has been identified as a risk factor for death and ICU admission due to COVID-19⁵⁶.

Mortality contributed (99.61%) towards almost all the DALYs due to the direct impact of COVID-19 in India, in line with other studies^{49,54,57}. There was a median of 31.67 YLLs per

COVID-19 death in India. This is because highest median YLLs were estimated for the population in the 51-60 year (3,906,065) and 61-70 year (3,256,690) age-groups, respectively. A study from two Indian states also reported that cases and deaths are concentrated in younger cohorts in the country as compared to high-income countries⁵⁸. Our DALY estimations were derived using the standard life expectancy table of Global Burden of Disease Study 2019⁴⁰. In Germany, 9.6 YLL per death have been reported; however, a higher YLL per death of 25.2 have been reported for persons under 70 years of age⁴⁹. YLL per COVID-19 death ranged from 15.3 to 15.5 in Scotland⁵⁹. However, these estimates could not be compared due to different life expectancy tables used in the analysis.

There are uncertainties surrounding these estimates. Undercounting or underreporting of COVID-19 cases and deaths is a serious concern and is more relevant in low- and middle-income countries such as India⁶⁰. We used IHME excess COVID-19 deaths and officially reported data to drive our estimates. As exact data on the total number of deaths during 2020 remain unavailable (India's Civil Registration System data), DALYs after accounting for the exact number of excess deaths could not be estimated. Grey literature indicates that there were 13,297 more deaths during March-September 2020 as compared to the same period in 2019 and 14,944 as compared in 2018 in Mumbai, India (<https://timesofindia.indiatimes.com/city/mumbai/13k-more-deaths-in-city-this-year-between-march-sept/articleshow/78920631.cms>). Conversely, the Kerala state of India reported an 11.1% reduction in all-cause mortality during 2020 as compared to 2019⁶¹ possibly due to high reduction in other cause mortality as compared to COVID-19 associated excess mortality. Globally, comparative analyses using COVID-19 attributable and excess death approaches indicate that YLL estimations using attributable deaths maybe 3 times lower than those accounting for excess deaths; however, these estimates maybe even 12 times lower in some countries¹³. To overcome this issue, we used excess mortality due to COVID-

19 from March 2020 to May 2021 as estimated by the IHME, Washington⁴¹. In addition, no data were available on age- and domain-specific proportions of excess deaths. We assumed this proportion to be similar to reported deaths. Therefore, the availability of all-cause mortality data in future will further refine COVID-19 associated DALY estimations in India. Furthermore, no data were available on the proportion of post-acute covid manifestations and was derived from other studies. This might have resulted in over or under estimation in the presented DALY. Lastly, indirect impact of COVID-19 especially due to disruption of health services could not be estimated.

Overall, direct impact of COVID-19 could be among the top 15 causes of DALYs in India. However, the estimated impact of COVID-19 would be substantially higher if indirect impacts of COVID-19 were to be accounted. Health impacts of COVID-19 varies in substantially in urban and rural areas. The current study will help to understand health impacts of COVID-19 in India and in other regions and countries.

ACKNOWLEDGEMENTS

The authors acknowledge India's National and State Health departments for collecting daily COVID-19 epidemic data and releasing it in the public domain.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ETHICAL STATEMENT

Informed consent for collection of epidemiological data was not required, as these data were already coded and available in the public domain. No identifiable personal information was used in this study.

AUTHOR CONTRIBUTORS

BBS conceived the study. NKD, MSK and BD contributed to the conceptual model development. BBS build the model and conducted the analyses. BBS prepared the first draft

of the paper which was reviewed and edited by NKD, MSK, HWB, ML, BS and BD. HWB and NKD coordinated the project and preparation of the manuscript.

ORCID

Balbir B Singh (0000-0002-6823-6146)

Herman W Barkema (0000-0002-9678-8378)

Navneet Dhand (0000-0002-4362-3596)

Brecht Devleesschauwer (0000-0002-2867-6892)

Mehar Khatkar (0000-0002-4554-1404)

DATA AVAILABILITY STATEMENT

The analysed data are available along with the manuscript. Sources of the raw data used in the analysis have been cited.

References

- 1 WHO. Listings of WHO's response to COVID-19. (2020).
<<https://www.who.int/news/item/29-06-2020-covidtimeline>>.
- 2 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).
- 3 Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. *Nature Medicine* **26**, 450-452, doi:10.1038/s41591-020-0820-9 (2020).
- 4 WHO. *WHO Coronavirus (COVID-19) dashboard*,
<<https://covid19.who.int/region/searo/country/in>> (2021).
- 5 Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J. & Hsueh, P.-R. J. I. j. o. a. a. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. *International Journal of*

- 321 *Antimicrobial Agents* **55**, 105924,
322 doi:<https://doi.org/10.1016/j.ijantimicag.2020.105924> (2020).
- 323 6 Somsen, G. A., van Rijn, C., Kooij, S., Bem, R. A. & Bonn, D. Small droplet aerosols
324 in poorly ventilated spaces and SARS-CoV-2 transmission. *The Lancet Respiratory*
325 *Medicine* **8**, 658-659, doi:10.1016/S2213-2600(20)30245-9 (2020).
- 326 7 Johnson, G. *et al.* Modality of human expired aerosol size distributions. *Journal of*
327 *Aerosol Science* **42**, 839-851 (2011).
- 328 8 Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
329 coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **395**, 507-
330 513, doi:10.1016/S0140-6736(20)30211-7 (2020).
- 331 9 Wang, D. *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel
332 coronavirus–infected pneumonia in Wuhan, China. *The Journal of American Medical*
333 *Association* **323**, 1061-1069, doi:10.1001/jama.2020.1585 (2020).
- 334 10 Nalbandian, A. *et al.* Post-acute COVID-19 syndrome. *Nature Medicine* **27**, 601-615,
335 doi:10.1038/s41591-021-01283-z (2021).
- 336 11 Singh, B. B. *et al.* Public health interventions slowed but did not halt the spread of
337 COVID-19 in India. *Transboundary and Emerging Diseases* **68**, 2171-2187,
338 doi:<https://doi.org/10.1111/tbed.13868> (2020).
- 339 12 Singh, B. B. *et al.* Meta-analysis and adjusted estimation of COVID-19 case fatality
340 risk in India and its association with the underlying comorbidities. *One Health*,
341 doi:10.1016/j.onehlt.2021.100283 (2021).
- 342 13 Pifarré i Arolas, H. *et al.* Years of life lost to COVID-19 in 81 countries. *Scientific*
343 *Reports* **11**, 3504, doi:10.1038/s41598-021-83040-3 (2021).
- 344 14 Denny, J., Narassima, M. S., Jaideep, C. M. & Guru Rajesh, J. Estimation of
345 economic burden of COVID-19 using disability-adjusted life years (DALYs) and

- productivity losses in Kerala state, India. *Research Square*, doi:10.21203/rs.3.rs-118146/v2 (2021).
- 15 MIB. *COVID 19 Tracker*. Ministry of Information and Broadcasting, Government of India., <<https://twitter.com/covidnewsbymib/status/1344505201332350977?lang=en>> (2020).
- 16 NCDC. *National Centre for Disease Control. COVID-19 Dashboard*., <<https://ncdc.gov.in/dashboard.php>> (2021).
- 17 Indrayan, A., Mishra, A. & Pathak, M. Preliminary Estimates of Years of Life Lost (YLL) Due to COVID-19 in India. *medRxiv*, 2020.2010.2024.20218693, doi:10.1101/2020.10.24.20218693 (2020).
- 18 PIB. *Press Information Bureau, Government of India. Updates on COVID-19*. Release ID: 1625744., <<https://pib.gov.in/PressReleasePage.aspx?PRID=1625744>> (2020).
- 19 Krishnasamy, N. *et al*. Clinical Outcomes among Asymptomatic or Mildly Symptomatic COVID-19 Patients in an Isolation Facility in Chennai, India. *The American Journal of Tropical Medicine and Hygiene* **104**, 85-90, doi:10.4269/ajtmh.20-1096 (2021).
- 20 Saurabh, S. *et al*. Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **115**, 820-831, doi:10.1093/trstmh/traa172 (2021).
- 21 Soni, S. L. *et al*. Demographic & clinical profile of patients with COVID-19 at a tertiary care hospital in north India. *Indian J Med Res* **153**, 115-125, doi:10.4103/ijmr.IJMR_2311_20 (2021).

- 370 22 Buitrago-Garcia, D. *et al.* Occurrence and transmission potential of asymptomatic and
371 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-
372 analysis. *PLOS Medicine* **17**, e1003346, doi:10.1371/journal.pmed.1003346 (2020).
- 373 23 PIB. *Press Information Bureau, Government of India. Home/All Press Release.*
374 *Others. PIB'S daily bulletin on COVID-19.,*
375 <<https://pib.gov.in/PressReleasePage.aspx?PRID=1639305>;
376 <https://pib.gov.in/PressReleasePage.aspx?PRID=1651364>> (2020).
- 377 24 Greenhalgh, T., Knight, M., A'Court, C., Buxton, M. & Husain, L. Management of
378 post-acute covid-19 in primary care. *BMJ* **370**, m3026, doi:10.1136/bmj.m3026
379 (2020).
- 380 25 CSS. *COVID symptom study. How long does COVID-19 last? Kings College London,*
381 *2020.,* <[https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-](https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI-)
382 [EFjh_aI-](https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI-)> (2020).
- 383 26 Moreno-Pérez, O. *et al.* Post-acute COVID-19 syndrome. Incidence and risk factors:
384 A Mediterranean cohort study. *J Infect* **82**, 378-383, doi:10.1016/j.jinf.2021.01.004
385 (2021).
- 386 27 Logue, J. K. *et al.* Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA*
387 *Network Open* **4**, e210830-e210830, doi:10.1001/jamanetworkopen.2021.0830
388 (2021).
- 389 28 Wyper, G. M. A. *et al.* Burden of Disease Methods: A Guide to Calculate COVID-19
390 Disability-Adjusted Life Years. *Int J Public Health* **66**, 1-5,
391 doi:10.3389/ijph.2021.619011 (2021).
- 392 29 Haagsma, J. A. *et al.* Assessing disability weights based on the responses of 30,660
393 people from four European countries. *Population Health Metrics* **13**, 10,
394 doi:10.1186/s12963-015-0042-4 (2015).

- 395 30 Salomon, J. A. *et al.* Disability weights for the Global Burden of Disease 2013 study.
396 *The Lancet Global Health* **3**, e712-e723, doi:10.1016/S2214-109X(15)00069-8
397 (2015).
- 398 31 James, S. L. *et al.* Global, regional, and national incidence, prevalence, and years
399 lived with disability for 354 diseases and injuries for 195 countries and territories,
400 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *The*
401 *Lancet* **392**, 1789-1858, doi:10.1016/S0140-6736(18)32279-7 (2018).
- 402 32 Kirtana, J. *et al.* Mild COVID-19 infection-predicting symptomatic phase and
403 outcome: A study from AIIMS, New Delhi. *J Family Med Prim Care* **9**, 5360-5365,
404 doi:10.4103/jfmpe.jfmpe_1610_20 (2020).
- 405 33 Agarwal, A. *et al.* Convalescent plasma in the management of moderate covid-19 in
406 adults in India: open label phase II multicentre randomised controlled trial (PLACID
407 Trial). *BMJ* **371**, m3939, doi:10.1136/bmj.m3939 (2020).
- 408 34 Pannu, A. *et al.* Severe Acute Respiratory Infection Surveillance during the Initial
409 Phase of the COVID-19 Outbreak in North India: A Comparison of COVID-19 to
410 Other SARI Causes. *Indian Journal of Critical Care Medicine* **25**, 761-767.,
411 doi:10.5005/jp-journals-10071-23882 (2021).
- 412 35 Daher, A. *et al.* Clinical course of COVID-19 patients needing supplemental oxygen
413 outside the intensive care unit. *Scientific Reports* **11**, 2256, doi:10.1038/s41598-021-
414 81444-9 (2021).
- 415 36 Shukla, U., Chavali, S., Mukta, P., Mapari, A. & Vyas, A. Initial Experience of
416 Critically Ill Patients with COVID-19 in Western India: A Case Series. *Indian J Crit*
417 *Care Med* **24**, 509-513, doi:10.5005/jp-journals-10071-23477 (2020).

418 37 Faes, C. *et al.* Time between Symptom Onset, Hospitalisation and Recovery or Death:
419 Statistical Analysis of Belgian COVID-19 Patients. *Int J Environ Res Public Health*
420 **17**, 7560, doi:10.3390/ijerph17207560 (2020).

421 38 WorldBank. *Population, total – India.*,
422 <<https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN>> (2020).

423 39 COI. *Census of India 2011. Population enumeration data (Final population)*,
424 <http://censusindia.gov.in/2011census/population_enumeration.html;
425 <http://censusindia.gov.in/2011-prov-results/indiaatglance.html>> (2011).

426 40 GBDCN. *Global Burden of Disease Collaborative Network. Global Burden of*
427 *Disease Study 2019 (GBD 2019) Reference Life Table. Seattle, United States of*
428 *America: Institute for Health Metrics and Evaluation (IHME).* ,
429 <<https://doi.org/10.6069/1D4Y-YQ37>> (2021).

430 41 IHME. *Institute for Health Metrics and Evaluation. Estimation of total mortality due*
431 *to COVID-19.* , <[http://www.healthdata.org/special-analysis/estimation-excess-](http://www.healthdata.org/special-analysis/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths)
432 [mortality-due-covid-19-and-scalars-reported-covid-19-deaths](http://www.healthdata.org/special-analysis/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths)> (2021).

433 42 CIFPC. Confidence Interval For Proportions Calculator. (2021).
434 <<https://stats.libretexts.org/@go/page/8347>>.

435 43 Devleesschauwer, B. *et al.* Calculating disability-adjusted life years to quantify
436 burden of disease. *International Journal of Public Health* **59**, 565-569,
437 doi:10.1007/s00038-014-0552-z (2014).

438 44 Devleesschauwer, B. *et al.* DALY calculation in practice: a stepwise approach.
439 *International Journal of Public Health* **59**, 571-574, doi:10.1007/s00038-014-0553-y
440 (2014).

441 45 Vos, T. *et al.* Global burden of 369 diseases and injuries in 204 countries and
442 territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
443 2019. *The Lancet* **396**, 1204-1222, doi:10.1016/S0140-6736(20)30925-9 (2020).

444 46 Menon, G. R. *et al.* National Burden Estimates of healthy life lost in India, 2017: an
445 analysis using direct mortality data and indirect disability data. *The Lancet Global*
446 *Health* **7**, e1675-e1684, doi:10.1016/S2214-109X(19)30451-6 (2019).

447 47 Wyper, G. *et al.* Inequalities in population health loss by multiple deprivation:
448 COVID-19 and pre-pandemic all-cause disability-adjusted life years (DALYs) in
449 Scotland. *SocArXiv js3h6*, doi:DOI: 10.31219/osf.io/js3h6 (2021).

450 48 Jo, M. W. *et al.* The Burden of Disease due to COVID-19 in Korea Using Disability-
451 Adjusted Life Years. *J Korean Med Sci* **35**, e199-e199,
452 doi:10.3346/jkms.2020.35.e199 (2020).

453 49 Rommel, A. *et al.* The COVID-19 Disease Burden in Germany in 2020. *Dtsch Arztebl*
454 *International* **118**, 145-151 (2021).

455 50 Quast, T., Andel, R., Gregory, S. & Storch, E. A. Years of life lost associated with
456 COVID-19 deaths in the USA during the first year of the pandemic. *Journal of Public*
457 *Health*, doi:10.1093/pubmed/fdab123 (2021).

458 51 Huang, Q. *et al.* Urban-rural differences in COVID-19 exposures and outcomes in the
459 South: A preliminary analysis of South Carolina. *PLoS One* **16**, e0246548,
460 doi:10.1371/journal.pone.0246548 (2021).

461 52 Kumar, S. *et al.* Who interacts with whom? Social mixing insights from a rural
462 population in India. *PLoS One* **13**, e0209039, doi:10.1371/journal.pone.0209039
463 (2018).

464 53 Chen, J. *et al.* Effect of modelling slum populations on influenza spread in Delhi.
465 *BMJ open* **6**, e011699-e011699, doi:10.1136/bmjopen-2016-011699 (2016).

466 54 Nurchis, M. C. *et al.* Impact of the Burden of COVID-19 in Italy: Results of
467 Disability-Adjusted Life Years (DALYs) and Productivity Loss. *Int J Environ Res*
468 *Public Health* **17**, 4233, doi:10.3390/ijerph17124233 (2020).

469 55 Oh, I. H. *et al.* Years of Life Lost Attributable to COVID-19 in High-incidence
470 Countries. *J Korean Med Sci* **35**, e300-e300, doi:10.3346/jkms.2020.35.e300 (2020).

471 56 Peckham, H. *et al.* Male sex identified by global COVID-19 meta-analysis as a risk
472 factor for death and ICU admission. *Nature Communications* **11**, 6317,
473 doi:10.1038/s41467-020-19741-6 (2020).

474 57 Zhao, J. *et al.* Disease Burden Attributable to the First Wave of COVID-19 in China
475 and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies.
476 *Value in Health* **24**, 615-624, doi:10.1016/j.jval.2020.12.009 (2021).

477 58 Laxminarayan, R. *et al.* Epidemiology and transmission dynamics of COVID-19 in
478 two Indian states. *Science* **370**, 691, doi:10.1126/science.abd7672 (2020).

479 59 Wyper, G. *et al.* Measuring the direct population impact of COVID-19 in Scotland,
480 2020: estimating disability-adjusted life years (DALYs) during the first full calendar
481 year., doi:10.31235/osf.io/ey36d (2021).

482 60 Li, Y. & Nair, H. How reliable are COVID-19 burden estimates for India? *The Lancet*
483 *Infectious Diseases*, doi:10.1016/S1473-3099(21)00422-9 (2021).

484 61 DHFW. *Technical paper COVID 19. Reduction in all-cause mortality in Kerala*
485 *during COVID-19 pandemic.*, <[https://health.kerala.gov.in/pdf/Technical-paper-All-](https://health.kerala.gov.in/pdf/Technical-paper-All-Cause-Mortality-Kerala.pdf)
486 [Cause-Mortality-Kerala.pdf](https://health.kerala.gov.in/pdf/Technical-paper-All-Cause-Mortality-Kerala.pdf)> (2021).

491 **Table 1: Estimated annual disability adjusted life years (DALYs) due to excess COVID-19 deaths in 2020 in India.**

	Median YLL	95% UI	Median YLD	95% UI	Median DALY	95% UI
Total	13,992,709	13,958,073– 14,027,485	105,784	50,002–217,970	14,100,422	14,030,129– 14,213,231
Domain						
<i>Rural</i>	6,102,220	6,087,116– 6,117,386	31,253	14,773–64,397	6,134,167	6,109,995– 6,168,716
<i>Urban</i>	7,890,488	7,870,957– 7,910,099	74,530	35,229–153,573	7,966,143	7,919,750– 8,045,000
Gender						
<i>Male</i>	8,955,334	8,933,167– 8,977,590	68,275	32,273–140,681	9,024,833	8,979,611– 9,097,629
<i>Female</i>	5,037,375	5,024,906– 5,049,895	37,508	17,729–77,289	5,075,566	5,050,493– 5,115,612
	Median YLL/100,000 person years	95% UI	Median YLD/100,000 person years	95% UI	Median DALY/100,000 person years	95% UI
Total	1,014	1,011–1,016	8	4–16	1,022	1,017–1,030
Domain						
<i>Rural</i>	642	641–644	3	2–7	646	643–649
<i>Urban</i>	1,836	1,831–1,840	17	8–36	1,854	1,842–1,872
Gender						
<i>Male</i>	1,261	1,258–1,264	10	5–20	1,270	1,264–1,281
<i>Female</i>	752	750–754	6	3–12	758	754–764

492 95% UI = 2.5–97.5th percentile

Table 2: Estimated annual disability-adjusted life years (DALYs) due to excess COVID-19 deaths in various age groups in 2020 in India.

Age (years)	Median DALYs	95% UI	Median DALY per 100,000 person-years	95% UI
Total	14,100,422	14,030,129–14,213,231	1022	1,017–1,030
<i>0-10</i>	189,636	187,389–194,019	61	61–63
<i>11-20</i>	237,600	233,106–246,611	83	81–86
<i>21-30</i>	760,728	748,089–785,869	311	306–322
<i>31-40</i>	1,485,568	1,472,653–1,509,745	758.4	752–771
<i>41-50</i>	2,652,051	2,639,491–2,671,686	1,822	1,814–1,836
<i>51-60</i>	3,921,906	3,908,098–3,939,808	4,069	4,055–4,088
<i>61-70</i>	3,265,799	3,255,655–3,277,308	5,001	4,986–5,019
<i>71-80</i>	1,326,741	1,322,679–1,331,288	5,481	5,464–5,499
<i>81-90</i>	245,109	244,293–246,096	3,805	3,793–3,821
<i>> 90 years</i>	15,072	14,996–15,194	714	710–720

95% UI = 2.5–97.5th percentile